Ph.D. molecular pharmacologist turning complex biology into platforms, patents, and decisions - across antimicrobial pharmacology, the human microbiome, and translational evidence.
From the mechanism of resistance to the message that moves a program forward - I build the evidence, translate it, and make it usable for the people who decide.
I build mechanism-first platforms - from FtsZ chemical biology and antimicrobial pharmacology to biofilm, microbiome, and 3D-tissue models - that turn biological complexity into decision-grade, translational evidence.
I translate complex data into clear, credible narratives - claims substantiation, technical briefs, evidence synthesis, and KOL-ready insight - adapting depth for scientists, regulators, commercial teams, and leadership.
I use LLM workflows, Python/R pipelines, and structural tools like AlphaFold to accelerate literature synthesis, QC, and biomedical reasoning - without replacing scientific judgment - so teams move faster and think more clearly.
Translating complex biomedical evidence into decisions, communication, and real-world health impact.
I am a Ph.D. scientist working at the intersection of mechanistic biology, translational research, scientific communication, and AI-enabled evidence generation. My career has focused on turning complex biomedical questions into measurable platforms, clear scientific narratives, and evidence packages that support decisions across discovery, regulatory strategy, product development, and health communication.
My foundation lies in cellular pharmacology and microbiology (Ph.D., Rutgers; M.S., UPR-Mayagüez), spanning early research at NASA Ames and MD Anderson Cancer Center to pioneering FtsZ antimicrobial targets. I bridge discovery and application, having engineered bacteriophage solutions, synthetic gene constructs, and 3D-tissue models to combat multidrug-resistant pathogens and target complex diseases.
Within the consumer goods industry, I drive consumer-focused evidence generation and manage robust strategic portfolios. Equipped with a Google Project Management Certificate and bilingual fluency (English/Spanish), I align rigorous R&D-from Python/R data analytics to clinical evaluations-with commercial realities and regulatory strategies.
Data only matters if it drives action. I specialize in distilling high-dimensional biological data into executive insights and compelling narratives. As a trusted peer reviewer for top-tier journals (Nature Microbiology, Nature Communications) and a recognized fellow (NIH Bridges, UPRM-HHMI), I am committed to advancing scientific rigor while actively mentoring the next generation of scientists.
I am deeply driven by the intersection of the microbiome and human health, exploring how targeted interventions - from bacteriophages and genetic engineering to novel materials and antibiotics - can disrupt biofilms and combat multidrug resistance. My interests span the therapeutic role of the microbiome in skin disorders and cancer, alongside leveraging AI/ML biological models to accelerate drug discovery. Ultimately, my goal is to translate these mechanistic insights into consumer health innovations and clinical healthcare solutions that tangibly improve patient outcomes.
From discovery through patent to commercialization, listed by release year with the newest work first.
Characterization of vulvar microbiome ecology across life stages, health status, and functional signatures.
Novel fluorescent probes designed to target the FtsZ protein for real-time visualization of division machinery. Licensed and commercialized via MilliporeSigma.
Discovery of a benzamide FtsZ inhibitor with strong bactericidal activity and in vivo efficacy against multidrug-resistant MRSA.
Demonstrates how FtsZ inhibition can restore and potentiate beta-lactam performance against MRSA.
Identification of MreB-targeting small molecules with antibacterial activity against Gram-negative pathogens.
Mechanistic study connecting FtsZ inhibition to altered localization of penicillin-binding proteins in MRSA.
Structure-guided probe design enabling visualization of FtsZ across clinically relevant pathogens.
Identifies beta-lactams with high PBP2 affinity that maximize synergy with FtsZ inhibition against MRSA.
Insights on microbiology, scientific practice, and the systems that shape them.
Exploring the mechanistic models driving modern drug discovery and how systems-level thinking reshapes translational science.
Platform ownership examples illustrating transferable, systems-level scientific leadership. Click any card to launch the interactive simulation workbench.
Designing mechanistic and translational platforms to combat antimicrobial resistance by breaking persistence, transmission, and treatment failure across clinical and consumer environments.
Understanding and disrupting microbial systems-biofilms, communities, and host–microbe interactions-to reduce chronic infection risk and improve intervention durability.
Translating molecular and cellular mechanisms into decision-grade evidence that informs therapeutic strategy, candidate selection, and resistance-mitigation approaches.
Building scalable assay systems, analytics, and scientific narratives that turn complex biological data into confident decisions across R&D, regulatory, and product teams.
I build the mechanistic foundation, translate it across audiences, and communicate with the precision that moves things forward.